pois toughest year maintain
fve control pipelin
updat forecast estim feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim feb
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
root provid supportive-car product kidney
diseas cancer patient free cash flow percentag
sale hover firm benefit massiv
cost-cut
blockbust like prolia/xgeva futur blockbust cholesterol
drug repatha defend wide moat eros due
biosimilar brand competit
biolog vulner biosimilar
age eas manufactur innov brand drug
also steal share tougher label reimburs
affect anemia drug epogen aranesp sinc safeti concern
emerg launch biosimilar retacrit
weigh sale beyond neutropenia drug
biosimilar competit year
key longer-act drug neulasta begin see declin
key market due two biosimilar launch
effect brand competitor pois continu erod
enbrel share enbrel patent run think
biosimilar humira expect could pull
sale tnf class
address headwind invest heavili
effici manufactur undertaken massiv cost-cut
program defend margin re-invest promot
new area like cardiolog larg biosimilar pipelin
begin launch europ low manufactur
cost could make viabl competitor nascent market
newer drug pipelin also key counter
biosimilar version older drug prolia osteoporosi xgeva
fractur prevent cancer patient see
billion peak sale kyproli -- acquir onyx
pois becom billion product multipl myeloma
repatha cholesterol-low look like biggest opportun
estim billion peak sale also bullish
posit aimovig launch migrain
tezepelumab phase asthma phase
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer support care product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli recent launch includ repatha
cholesterol-low aimovig migrain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
maintain fve control pipelin
maintain fair valu estim amgen
follow in-lin result disappoint guidanc
slightli reduc sale forecast
legaci product reflect steep
competit price pressur larg maintain
forecast newer brand portfolio
increas biosimilar portfolio
assumpt howev cost control key
valuat despit heavi biosimilar pressur neulasta
epogen oper expens pois stay
rel flat minim oper margin pressur
allow see posit ep growth
help share repurchas
share recent trade slight discount
valuat think wide moat remain
support core product prolia/xgeva newer launch
repatha cholesterol lower aimovig migrain
earli pipelin multipl oncolog program asthma
drug tezepelumab enbrel sensipar patent litig
remain risk valuat although alreadi
substanti declin sensipar built model
patent settlement
acceler double-digit declin remaind
forecast enbrel due brand competit
upsid aimovig estim remain consensu
launch acceler exceed estim
could increas valuat addit sever early-stag
oncolog trial read includ once-weekli
bcma-target biolog could boost long-
neulasta face two biosimilar competitor unit
state far -- fulphila coheru
udenyca -- potenti third end year list
price fulphila udenyca third lower
neulasta neulasta discount on-bodi
deliveri system market make biosimilar
slightli less compel increas neulasta
declin base initi traction
fulphila cautiou commentari overal
price commentari estim mid-single-digit
price pressur portfolio epogen
face retacrit biosimilar offer
similar discount neulasta biosimilar epogen
contract offer mitig
potenti volum declin epogen
sale also includ stage price declin
detail patent exposur pipelin
pleas see recent healthcar observ annual drug
pipelin report moat remain secur innov
counter price gener headwind
acceler report also discuss view large-
scale industri cash balanc
billion strong free cash flow gener give
mean take action lacklust intern growth
rais fair valu estim per share
incorpor phase pipelin drug
target bcma think firm capabl
averag top-lin sale growth bottom-lin
growth enbrel profit share pfizer
end signific cost-cut non-gaap oper
margin improv nearli
expect margin remain even
addit invest sg due stronger
also give us increas confid potenti
biosimilar pipelin compet global
includ billion biosimilar sale
price power erod think enbrel sale
continu declin brand aranesp competit
mircera well epogen biosimilar launch
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
capit cost assumpt return equiti investor
like demand long run
access previous off-shore cash expect firm
emphas dividend share repurchas
model slightli declin gross debt level near term
note debt level could easili increas amgen
pre-tax cost debt reflect normal long-term
confid capabl defend
bottom-lin key period weak legaci
product cost-cut manufactur innov help
trim oper cost howev abil grow
heavili depend repatha abil move past payer
restrict well futur potenti restrict
aimovig migrain even osteoporosi
therefor assign diversifi biotech medium
repatha sale assumpt well futur oper
margin key assumpt behind fair valu
estim base-cas scenario assum adjust
oper margin declin remain
royalti sale praluent revenu
repatha praluent reach billion
bull-cas scenario assum improv adjust
oper margin exceed assum
obtain royalti sale praluent
revenu hit billion
result fair valu estim per share
bear-cas scenario assum adjust oper
margin declin repatha
sale billion assum praluent royalti
persist difficulti payer reimburs result
weigh anemia drug sale expect neulasta sale
begin fall significantli biosimilar launch
 market assum averag annual declin
neutropenia
neulasta
next year
expect combin prolia/xgeva sale peak
billion also forecast peak cholesterol-low sale
billion includ repatha sale well assum
royalti praluent sale begin
peak sale migrain drug aimovig around billion
assign probabl approv even
osteoporosi assum peak global sale billion
also see newer cancer drug like blincyto imlyg
smaller opportun billion peak despit
posit data endeavor studi
multipl myeloma market gotten
competit think sale onyx kyproli could
peak billion
assum cost capit still rate
systemat risk surround share
averag cost equiti assumpt align
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fair valu estim per share
market sever blockbust biolog therapi
oncolog immunolog market give
intang asset form foundat wide moat
one origin biotech launch innov
anemia neutropenia
begin epogen
longer-act product aranesp neulasta
launch firm decid acquir
immunex bring enbrel portfolio highli
profit biolog continu drive strong free cash
flow firm gener around sale expect
see steadi free cash flow margin level
return invest capit remain cost
capit forese futur
continu grow despit steadi regulatori
epogen aranesp sinc well biosimilar
competit anemia neutropenia drug
establish europ nascent gener
biosimilar pressur sever biolog
larg
manufactur difficulti cost clinic trial
product market creat high barrier entri
limit number entrant addit amgen
longer-act product aranesp neulasta help
defend biosimilar threat older product
also highli diversifi enbrel account
sale repatha pois top
product sale strong growth enbrel
neutropenia drug counter epogen aranesp
headwind past year prolia/xgeva
approv osteoporosi cancer indic
reach blockbust statu renal diseas
drug sensipar onyx acquisit multipl
myeloma drug kyproli gener strong data
expand sale support european launch
competit like prevent signific uptak
see moat trend stabl think newli
launch product higher rate product
late-stag pipelin -- brand biosimilar -- allow
firm sustain strong roic new lower-cost
manufactur technolog aggress cost-cut
effort price volum pressur biosimilar
competit weigh heavili long-term margin
reimburs new competit brand
biosimilar biggest headwind moat
trend reimburs dialysi drug epogen bundl
dialysi product although contract
competit price margin pressur
product also among oldest --
profit -- market biolog mani among
first see biosimilar competit key patent
epogen neulasta expir
three product account top line
biosimilar competit europ mild
impact epogen sale focus
 brand neulasta shield
biosimilar competit neulasta sale
 howev epogen biosimilar
biosimilar neulasta coheru
launch overal expect
averag annual sale declin epogen
neutropenia franchis addit arthriti
psoriasi drug enbrel see high level new
competit assum double-digit sale declin
begin ahead humira biosimilar launch
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
top
howev regard pipelin product think amgen
turn corner think firm abl
line despit pressur current
blockbust histor high failur rate
pipelin particularli oncolog pipelin
decis return brodalumab
right astra due higher rate suicid also hit
late-stag pipelin howev cholesterol drug
repatha launch europ
despit slow start expect antibodi class
could gener billion peak sale
sanofi/regeneron praluent remain well ahead key
candid even met key superior endpoint forteo
phase trial cardiovascular side
drug
bone-form mechan action could complement
prolia migrain drug aimovig launch
could see billion peak potenti
limit broad uptak
also bullish abil compet
biosimilar market given firm effici manufactur
practic establish oncolog immunolog salesforc
regulatori legal expertis advanc pipelin
assum partner allergan hold
share global biosimilar market
believ manufactur improv could boost
biosimilar emerging-market opportun
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pipelin product sinc
launch prolia/xgeva cholesterol drug repatha
migrain drug aimovig reviv
enthusiasm firm research engin
obiosimilar market europ sinc
biosimilar could larger impact
version epogen neulasta hit
acquisit decod give firm
abil identifi potenti new drug target valid
human genet
improv manufactur effici
benefit gross margin also could give firm
cost advantag nascent biosimilar market
alreadi launch two product europ
oth payoff billion acquisit
onyx highli depend success kyproli
johnson johnson/genmab darzalex
bcma-target therapi like strong
lack focu biotech peer
drug target larg market like osteoporosi
cardiolog specialti market like immunolog
oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end held billion cash
billion debt expect gener roughli
billion free cash flow annual next year
combin one-tim repatri off-shore cash
end suffici handl
debt come due well firm share-repurchas
program billion author repurchas end
dividend program dividend rise
surpass billion
biosimilar uptak remain biggest risk
neulasta epogen biosimilar
launch regulatori reimburs chang
could continu plagu aranesp epogen includ
medicar dialysi reimburs cut enbrel key
growth driver grow competit
rheumatoid arthriti psoriasi could weigh
firm market share price power evapor
overal price power could wane propos
medicar part reimburs
implement given firm relianc medicar
high proport sale addit sever
newer product enter highli competit market
prolia compet establish drug novarti
reclast cheaper gener bisphosphon vectibix
compet roch avastin eli lilli
kyproli lead proteasom inhibitor velcad
posit comparison fail differenti
kyproli first-lin set billion
acquisit onyx could prove expens repatha
shown signific abil reduc advers cardiovascular
event benefit may enough loosen payer
restrict limit patient access drug aimovig
also enter crowd market similar drug
entrant eager discount price gain share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mr robert bradwayceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund invmt co amer
america corpor
new york mellon corp
capit research manag compani
share
fund
share
fund
assign amgen standard mark stewardship
firm research develop engin
struggl churn promis drug candid sinc
launch prolia/xgeva believ new blood might
benefici firm product futur share
perform sale profit skyrocket
reign ceo chairman kevin sharer
signific multipl compress led flat perform
firm share tenur former presid
bob bradway replac sharer ceo may
board chairman start bradway
advanc sinc arriv vice presid
oper wish firm select
someon longer record pharmaceut industri
bradway morgan stanley
year think experi would particularli use
firm face steep biosimilar competit
need cohes strategi hope keep top-lin
growth posit territori said cfo david melin
appear make necessari cost cut
perlmutt head research develop retir
februari replac sean harper harper
sinc think medic background
experi senior vice presid global
develop serv well
make sever shareholder-friendli
move recent histori share repurchas tender
offer level fair valu estim appear
good use cash quarterli dividend grew roughli
annual initi level howev
remain wari firm compens polici
reward execut easili manipul earn per
share growth instead return invest capit
board structur enough healthcare-rel experi
board member former ceo robert
eckert phillip ceo greg garland
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
strong aimovig/parsabiv launch
counter lower repatha/kyproli estim oct
maintain per share fair valu estim
follow solid third-quart perform
see new product line-up grow phase
pipelin support stabl wide moat despit
biosimilar threat older drug manag rais
revenu ep guidanc year slightli
increas top bottom-lin assumpt much
hing stronger revenu third quarter
strong launch kidney diseas drug parsabiv
howev slightli lower forecast multipl
myeloma drug kyproli base disappoint recent
perform competit market also
lower estim cholesterol drug repatha
account volum increas slower
anticip
said encourag decis
introduc new nation drug code repatha
lower price help patient
prescript afford signific pocket cost
medicar patient assist
program allow roughli price
new repatha code fit well previou assumpt
price addit anticip data annual
meet american societi hematolog
phase bcma-target bispecif multipl
myeloma earli data fall hand patient
encourag recent move sever
new drug phase develop data report
program advanc mid-stag
develop plan incorpor model
traction effort rein drug spend
includ confirm medicar advantag step
therapi well recent propos extrem
chang medicar part could affect
firm given firm signific exposur
market specif medic benefit pleas see
healthcar observ drug price reform weigh
valuat moat look secur drug
industri look under-valued detail far
key risk perform believ
incorpor reason headwind includ
time sensipar gener competit assum late
extent neulasta eros new
biosimilar fulphila alreadi market
assum declin remain
consensu migrain drug aimovig sale potenti
despit strong launch given tough competit
landscap lilli teva receiv approv
similar drug shortli first-in-class approv
may
oct presid trump outlin potenti action
price drug cover medicar part
administ hospit physician offic
weigh investor sentiment surround government-
led drug price reform announc time
ahead novemb elect follow trump
sign yesterday support bill fight opioid
epidem make fair valu chang
result announc sever signific
uncertainti make difficult assum signific
hit price first remain unclear whether result
actual reform propos industri reaction
comment period run end
could neg smaller fail
effort tweak part price obama
time impact also question demonstr
drug could start would
surpris implement delay beyond trump
first term
increas uncertainti around
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
price target price would lower overal would
vari depend drug price intern market
privat sector negoti competit acquisit
program implement fail think
size part program today could give greater
likelihood success could make part similar
part privat sector negoti via pbm help
control price
today hh report offer detail analysi
intern price highest-sel part
therapi conclud intern price
develop market larg europ canada japan
lower price basket drug
account part spend hh report note
biggest save could seen lower price
rituxan alreadi pois see biosimilar entrant
first half well neulasta also
face biosimilar threat ophthalmolog drug
regeneron eylea roch lucenti
report highlight trend drug approv
drug spend trump administr start
faster gener brand drug approv rate
also includ analysi support administr
impact price lower rate brand drug price
growth larger discount brand drug sinc earli
implement addit unclear drug would
specif target drug high part
spend similar price intern market see
immuno-oncolog drug ultra orphan diseas
therapi clear geographi would
particip initi demonstr project although
intend cover part spend final
compensatori price increas outsid could help
pharma/big biotech firm signific
exposur medicar part begin discuss
healthcar observ drug price reform
weigh valuat moat look secur drug
biotech industri look under-valued estim
firm highest exposur percentag drug
bristol-my squibb
sever new piec inform releas today
includ advanc notic propos rulemak
anprm hh report part drug price rel
price develop nation new council
date drug price
anprm follow request inform juli
part larger propos medicar outpati payment
rule allud possibl medicar part
demonstr project anprm discuss potenti
lower part spend save billion six-
year period use intern price
index model base basket intern price
privat sector negoti model would phase
 price five-year period begin spring
focus drug highest part spend
could initi target drug first two year
model one reliabl data intern drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
